Niemann-Pick Disease: Causes, Symptoms & Diagnosis

What Are the Main Types of Niemann-Pick Disease?

The major forms are classified by their genetic cause, the cellular process involved, and the pattern of symptoms. Although the traditional labels A, B, and C remain widely recognized, modern terminology better reflects the underlying biology.

Infantile Neurovisceral ASMD, Historically Type A

The severe infantile form of ASMD was historically known as Niemann-Pick disease type A. Symptoms usually begin during infancy. The condition affects both internal organs and the nervous system, causing rapid neurological decline.

Babies may appear healthy at birth and during their first few months. Later, parents may notice feeding problems, poor weight gain, an enlarged abdomen, weak muscle tone, loss of previously acquired skills, or reduced interaction with their surroundings. Lung disease and repeated respiratory infections may also occur.

Chronic Visceral ASMD, Historically Type B

The more slowly progressive form was traditionally called Niemann-Pick disease type B. It mainly affects the spleen, liver, lungs, blood, and skeletal system. Significant neurological deterioration is uncommon, although some people have intermediate symptoms that fall between the classic type A and type B descriptions.

Symptoms can begin in childhood, adolescence, or adulthood. Many affected people survive well into adulthood, but the severity varies considerably. One person may have mild enlargement of the spleen, while another may develop serious lung or liver complications.

Niemann-Pick Disease Type C

NPC is a progressive neurovisceral disorder. “Neurovisceral” means it can affect both the nervous system and internal organs. Symptoms may appear before birth, during infancy, in childhood, or even in adulthood.

Some infants initially have liver disease or prolonged jaundice. Children may later develop coordination problems, unusual eye-movement abnormalities, speech changes, swallowing difficulty, learning problems, or loss of previously mastered abilities. Teenagers and adults sometimes first receive psychiatric, cognitive, or movement-disorder diagnoses before NPC is recognized.

Evidence base: NIH GARD, NORD, GeneReviews, Boston Children’s Hospital and NCBI.

What Causes Niemann-Pick Disease?

All major forms of Niemann-Pick disease are caused by inherited gene variants. They usually follow an autosomal recessive inheritance pattern. This means an affected person receives one disease-causing gene variant from each biological parent.

Parents who carry only one altered copy generally do not develop the disease. When two carriers have a child together, each pregnancy typically carries:

• A 25% chance that the child will inherit both altered copies and have the condition.
• A 50% chance that the child will inherit one altered copy and be an unaffected carrier.
• A 25% chance that the child will inherit neither altered copy.

These probabilities begin again with every pregnancy. Having one unaffected child does not change the odds for the next child.

The Genetic Cause of ASMD

ASMD results from pathogenic variants in the SMPD1 gene. This gene provides instructions for producing acid sphingomyelinase, an enzyme located inside lysosomes.

Acid sphingomyelinase normally breaks down a lipid called sphingomyelin. When enzyme activity is extremely low, sphingomyelin accumulates in cells throughout the body. The degree of remaining enzyme activity partly influences the age of onset and severity, although genotype does not always predict an individual’s exact clinical course.

The Genetic Cause of NPC

NPC is caused by variants in either the NPC1 or NPC2 gene. Most diagnosed cases involve NPC1. The proteins produced by these genes help move cholesterol and other lipids through compartments inside cells.

When either protein does not work properly, cholesterol and related lipids become trapped in late endosomes and lysosomes. The resulting accumulation interferes with cell function and gradually damages tissues, particularly the brain, liver, spleen, and lungs.

This is an important distinction: ASMD primarily involves insufficient enzyme activity, while NPC involves defective intracellular lipid trafficking. The conditions may share symptoms, but their biological causes and diagnostic tests are not identical.

Evidence base: NCBI StatPearls, MedlinePlus Genetics, NORD, GARD and GeneReviews.

Common Symptoms of Niemann-Pick Disease

Niemann-Pick disease symptoms vary widely. Even relatives with the same diagnosis may have different ages of onset and rates of progression. Symptoms generally reflect which organs have accumulated the most damaging amounts of lipids.

Liver and Spleen Symptoms

An enlarged spleen, known as splenomegaly, is one of the most common findings in ASMD and NPC. An enlarged liver, or hepatomegaly, may occur at the same time. Together, the condition is called hepatosplenomegaly.

Possible signs include:

• A swollen or unusually firm abdomen.
• Discomfort or fullness beneath the ribs.
• Reduced appetite because the enlarged organs press on the stomach.
• Low platelet counts and easy bruising.
• Abnormal liver enzymes.
• Jaundice or prolonged newborn jaundice.
• Progressive liver dysfunction in severe cases.

Lung and Breathing Problems

Lipid-filled cells can accumulate in lung tissue, particularly in ASMD. This may produce interstitial lung disease, reduced exercise tolerance, low blood oxygen levels, frequent respiratory infections, shortness of breath, or a persistent cough.

Lung involvement may progress quietly. A person can have significant abnormalities on imaging or pulmonary function testing before noticing severe breathlessness.

Growth, Bone, and Blood Abnormalities

Children with chronic ASMD may grow more slowly than expected or enter puberty later than their peers. Reduced bone mineral density can increase the risk of fractures. Blood tests may reveal low platelets, anemia, abnormal cholesterol levels, or elevated triglycerides.

Neurological Symptoms

Neurological decline is prominent in severe infantile ASMD and NPC. Possible symptoms include:

• Low muscle tone or muscle weakness.
• Delayed development or loss of developmental milestones.
• Unsteady walking and poor coordination.
• Tremors, dystonia, or abnormal muscle contractions.
• Slurred or increasingly difficult speech.
• Difficulty chewing or swallowing.
• Seizures.
• Declining school performance or cognitive abilities.
• Progressive problems with memory, attention, or planning.

The Eye-Movement Clue in NPC

One of the most recognizable neurological clues for NPC is vertical supranuclear gaze palsy. Affected people have difficulty voluntarily moving their eyes upward or downward, although reflex eye movements may initially remain possible.

Children may compensate by moving their entire head instead of their eyes. Because this behavior can be subtle, it may be missed unless a clinician specifically examines vertical eye movements.

Gelastic Cataplexy

Some people with NPC experience gelastic cataplexy, a sudden loss of muscle tone triggered by laughter or another strong emotion. A child may briefly drop their head, buckle at the knees, or collapse while remaining conscious.

Because laughter triggers the event, families may initially assume the child is being playful. In the proper clinical context, however, gelastic cataplexy is an important diagnostic clue.

Behavioral and Psychiatric Symptoms

Adolescent- or adult-onset NPC may initially resemble a psychiatric illness. Symptoms can include depression, psychosis, hallucinations, disorganized behavior, impulsivity, declining work performance, or personality changes.

Psychiatric symptoms alone do not mean someone has NPC. Suspicion becomes stronger when they occur alongside unexplained coordination problems, abnormal eye movements, swallowing difficulty, cognitive decline, an enlarged spleen, or a relevant family history.

Evidence base: Mayo Clinic, MedlinePlus, NORD, GARD, Boston Children’s Hospital and Cleveland Clinic.

How Is Niemann-Pick Disease Diagnosed?

Diagnosis begins with recognizing a suspicious pattern. Because each individual symptom can have many possible causes, Niemann-Pick disease is often overlooked at first. The diagnostic process is less like finding one giant neon sign and more like following a trail of unusual breadcrumbs.

Medical History and Physical Examination

A clinician may ask about developmental progress, school performance, feeding, swallowing, breathing, bruising, recurrent infections, psychiatric changes, and similar symptoms among relatives. The physical examination may include:

• Measuring the liver and spleen.
• Assessing muscle tone, reflexes, balance, and walking.
• Checking speech and swallowing.
• Testing voluntary vertical eye movements.
• Looking for jaundice or unusual eye findings.
• Evaluating growth and developmental milestones.

Initial Laboratory and Imaging Tests

Routine tests cannot confirm Niemann-Pick disease, but they help define organ involvement and exclude more common conditions. Testing may include a complete blood count, liver-function tests, cholesterol and triglyceride measurements, abdominal ultrasound, chest imaging, pulmonary function testing, hearing assessments, and swallowing evaluations.

These results also provide a baseline for monitoring progression. For example, platelet counts can reflect the effects of an enlarged spleen, while pulmonary tests can reveal declining lung function before symptoms become dramatic.

Testing for Acid Sphingomyelinase Deficiency

When ASMD is suspected, clinicians measure acid sphingomyelinase activity in white blood cells, cultured cells, or a validated dried blood spot sample. Very low enzyme activity supports the diagnosis.

Molecular genetic testing of the SMPD1 gene is then used to identify disease-causing variants and confirm the diagnosis. Genetic results are also valuable for testing relatives, identifying carriers, and planning future pregnancies.

Testing for Niemann-Pick Disease Type C

Modern NPC evaluation may begin with blood-based biochemical biomarkers. These can include specific cholesterol oxidation products called oxysterols, lysosphingolipids, or bile-acid metabolites associated with abnormal intracellular cholesterol handling.

Genetic testing looks for disease-causing variants in NPC1 and NPC2. Finding two pathogenic or likely pathogenic variants consistent with the clinical picture can establish the diagnosis.

If biochemical and genetic results are uncertain, a specialist may recommend additional testing. Historically, filipin staining of cultured skin fibroblasts was widely used to show abnormal storage of unesterified cholesterol. It remains useful in selected unresolved cases but is no longer always the first test performed.

Why Bone Marrow Biopsy Is Usually Not the Best First Test

Bone marrow samples may show lipid-filled “foam cells,” but this finding is not specific to Niemann-Pick disease. Similar cells can occur in other storage disorders and medical conditions. Enzyme assays, biomarkers, and molecular testing provide more precise diagnostic information.

Prenatal and Carrier Testing

When a family’s disease-causing variants are known, carrier testing can identify relatives who carry one altered gene copy. Prenatal testing through chorionic villus sampling or amniocentesis may also be available.

Some families consider preimplantation genetic testing with in vitro fertilization. A genetic counselor can explain the accuracy, limitations, costs, timing, and emotional implications of each option without pushing a family toward one particular decision.

Evidence base: Mayo Clinic, MSD Manual, GeneReviews, MedlinePlus Genetics, GARD and NCBI.

Why Diagnosis Can Take So Long

Niemann-Pick disease can imitate more common disorders. An enlarged liver and spleen may suggest infection, leukemia, lymphoma, Gaucher disease, or another metabolic condition. Poor coordination may be attributed to cerebral palsy or a hereditary ataxia. Cognitive and behavioral changes may lead to an initial diagnosis of attention-deficit disorder, depression, bipolar disorder, schizophrenia, or early-onset dementia.

Age also complicates the picture. Clinicians may recognize rapidly progressive disease in an infant more readily than slowly emerging symptoms in a teenager or adult. When liver findings occurred years before neurological symptoms, no one may immediately connect the two.

Diagnostic suspicion should rise when symptoms cross several medical specialties. An unexplained combination of splenomegaly, abnormal eye movements, ataxia, swallowing problems, developmental regression, lung disease, or psychiatric decline deserves evaluation by a metabolic geneticist or neurologist familiar with lysosomal storage disorders.

What Happens After a Diagnosis?

There is no single care plan suitable for every patient. Management commonly involves a metabolic geneticist, neurologist, pulmonologist, gastroenterologist or liver specialist, physical therapist, occupational therapist, speech-language pathologist, dietitian, genetic counselor, and mental health professional.

Supportive care may address seizures, breathing problems, nutrition, swallowing safety, mobility, pain, sleep, communication, and school accommodations. Feeding-tube support may be considered when swallowing becomes unsafe or maintaining adequate nutrition is difficult.

FDA-approved therapies are now available for certain manifestations of these diseases. Olipudase alfa-rpcp, sold as Xenpozyme, is an enzyme replacement therapy approved for non-central-nervous-system manifestations of ASMD in adult and pediatric patients. It does not directly treat neurological damage.

For NPC, the FDA approved two treatments for neurological manifestations in September 2024. Arimoclomol, sold as Miplyffa, is approved in combination with miglustat for patients age 2 and older. Levacetylleucine, sold as Aqneursa, is approved for adults and children who weigh at least 15 kilograms. These treatments are not cures, and eligibility, benefits, risks, and monitoring requirements should be reviewed with an experienced specialist.

Evidence base: FDA approvals and prescribing information.

Experiences Families Commonly Face

The lived experience of Niemann-Pick disease often begins long before anyone says the disease’s name. A family may first notice that a baby’s abdomen looks unusually large, a child has trouble keeping up during recess, or a teenager has become clumsy and withdrawn. Each concern can appear minor when viewed alone. The difficulty is realizing that they belong to the same medical story.

Consider an illustrative example based on common diagnostic patterns. A child develops jaundice shortly after birth and is monitored until the liver tests improve. Several years later, teachers report that the child is struggling with handwriting, balance, and concentration. The family visits an eye doctor, a physical therapist, a pediatrician, and a neurologist. Every appointment produces another piece of information, but no single explanation.

Eventually, a clinician notices that the child moves their head rather than their eyes when looking down. The clinician also connects this sign with an enlarged spleen documented years earlier. NPC testing is ordered, and the diagnosis is confirmed. For the family, receiving the answer can bring two conflicting emotions at once: grief about the disease and relief that the search finally has a name.

After diagnosis, ordinary routines may become medical logistics. Breakfast can involve medications, modified food textures, and careful swallowing. School may require extra transition time, an individualized education program, mobility assistance, or permission to use communication technology. Family outings may be planned around fatigue, wheelchair access, medication schedules, and the nearest appropriate medical facility.

Appointments can also feel like a part-time job nobody applied for. Families may coordinate blood tests, pulmonary evaluations, neurological assessments, therapy sessions, insurance authorizations, specialty-pharmacy deliveries, and clinical follow-ups. Keeping a shared medical summary can help. Useful information includes the confirmed genetic variants, current medications, swallowing recommendations, seizure plan, recent imaging, emergency contacts, and names of specialists.

Siblings may need support as well. They can feel worried, overlooked, protective, embarrassed, or guilty for being healthy. Honest age-appropriate conversations and dedicated one-on-one time can reduce confusion. When appropriate, genetic counseling can explain whether siblings should consider carrier testing later in life.

Caregivers often learn to measure progress differently. Success might mean fewer falls, safer swallowing, a stable pulmonary test, a comfortable night’s sleep, or being able to participate in a favorite activity. These achievements may look small in a medical chart, but they can be enormous in daily life.

Support organizations and rare-disease communities can be valuable because other families already understand the unfamiliar vocabulary, insurance battles, equipment decisions, and emotional whiplash. Peer support should complement professional medical care, not replace it. A treatment or supplement that helped one person may be ineffective or unsafe for another.

Perhaps the most practical lesson is to document change. Families can record new falls, coughing during meals, episodes triggered by laughter, changes in handwriting, medication effects, and short videos of unusual movements. Specific observations often help clinicians more than broad statements such as “something seems worse.”

Living with Niemann-Pick disease requires flexibility, advocacy, and a multidisciplinary team that listens. Families do not need to become molecular biologists overnight, although many eventually sound impressively close. They do need clear information, coordinated care, realistic goals, and room to remain a family rather than becoming a full-time medical department.

When to Seek Medical Evaluation

Consult a healthcare professional when a child or adult has unexplained enlargement of the liver or spleen, developmental regression, worsening coordination, unusual vertical eye movements, recurrent lung problems, progressive swallowing difficulty, unexplained cataplexy, or neurological and psychiatric symptoms occurring together.

These findings are not proof of Niemann-Pick disease. Many more common conditions can cause them. However, early referral to a genetics or metabolic specialist can prevent unnecessary testing and shorten the path to an accurate diagnosis.

Conclusion

Niemann-Pick disease includes several rare inherited disorders in which abnormal lipid processing damages cells and organs. ASMD results from deficient acid sphingomyelinase activity caused by SMPD1 variants, while NPC results from impaired lipid transport associated with NPC1 or NPC2 variants.

Symptoms may involve the liver, spleen, lungs, blood, bones, eyes, movement, swallowing, cognition, and behavior. Because the presentation varies by type and age, diagnosis requires attention to the full pattern rather than any one symptom. Enzyme testing, biochemical biomarkers, and genetic analysis now make it possible to confirm the specific disorder more accurately.

Earlier diagnosis cannot erase the challenges of Niemann-Pick disease, but it can guide treatment, improve symptom management, connect families with experienced specialists, and provide reliable information for relatives and future family planning.

SEO Information